Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Husted

Psychiatry Palm Beach Gardens, FL Medical Doctor

NPI 1255370235 CMS profile 193232

3365 Burns Rd Ste 203, Palm Beach Gardens, FL 33410

Open in the dashboard

General payments

$8,889

338 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Husted of Palm Beach Gardens, FL is reported in the CMS Open Payments database as having received $8,889 across 338 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,078 76
2024 General $2,462 98
2023 General $1,651 89
2022 General $2,641 72
2021 General $21 1
2020 General $19 1
2019 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Husted
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to David Husted were reported at $2,078. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year David Husted Psychiatry median Middle half National median
2019 $17 $184 $59–$605 $163
2020 $19 $119 $36–$372 $114
2021 $21 $143 $43–$576 $132
2022 $2,641 $153 $50–$590 $149
2023 $1,651 $170 $56–$651 $160
2024 $2,462 $179 $57–$673 $164
2025 $2,078 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Brainsway USA Inc $1,663 1 payment
  2. AbbVie, Inc. $1,339 76 payments
  3. Janssen Pharmaceuticals, Inc $1,008 49 payments
  4. Neurocrine Biosciences, Inc. $919 46 payments
  5. Alkermes, Inc. $469 27 payments
  6. LivaNova USA, Inc. $414 10 payments
  7. Corium, Inc. $396 17 payments
  8. Otsuka America Pharmaceutical, Inc. $360 13 payments
  9. Teva Pharmaceuticals USA, Inc. $331 13 payments
  10. Axsome Therapeutics, Inc. $330 5 payments
  11. Other $1,661 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,226 337 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,663 1 payment
Products named General payments · program years 2019–2025
  1. BrainsWay Deep TMS $1,663 1 payment
  2. VRAYLAR $1,099 62 payments
  3. INGREZZA $883 44 payments
  4. SPRAVATO $681 25 payments
  5. LYBALVI Cns $455 26 payments
  6. Azstarys $396 17 payments
  7. VNS THERAPY SYMMETRY MODEL 8103 GENERATOR $393 9 payments
  8. REXULTI $360 13 payments
  9. INVEGA SUSTENNA $327 24 payments
  10. LYBALVI Cns $311 19 payments
  11. Other $4,061 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

3,009

Median for Psychiatry: 574

Drug cost

$502,665

Median for Psychiatry: $27,624

Branded share of claims

25.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 30 $248,946
Rexulti Brexpiprazole Brand 25 $52,237
Abilify Maintena Aripiprazole Brand 11 $36,078
Mounjaro Tirzepatide Brand 22 $22,905
Ozempic Semaglutide Brand 19 $17,023
Trintellix Vortioxetine Hydrobromide Brand 18 $16,855
Vyvanse Lisdexamfetamine Dimesylate Brand 30 $11,254
Lurasidone Hcl Generic 32 $7,411
Belsomra Suvorexant Brand 12 $5,966
Clozapine Generic 79 $5,914

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$213,344

Medicare's payments for the services billed

Medicare patients

118

Average age 69

Services billed

2,048

74 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 67%
Arthritis 57%
Osteoporosis 28%
Diabetes 27%
Ischemic heart disease 26%
Chronic kidney disease 24%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $463
$463 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $204
  • Lundbeck LLC $108
$312 25 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $239
$239 — —
Auvelity
  • Axsome Therapeutics, Inc. $155
$155 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $152
$152 30 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

338 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record